Torrent Pharmaceuticals (500420) Q4 96/97 earnings summary

Executive summary

• Refocused operations on pharmaceuticals, divested non-pharma holdings and acquired pharma export operations; total sales rose 6% to Rs317.94 crore for FY97.

• Domestic formulation sales grew 21%, above the 15% industry average; May 1997 domestic sales ranking improved to No. 6.

Financial highlights

• FY97 sales were Rs317.94 crore vs Rs298.73 crore; PBT Rs34.03 crore vs Rs33.27 crore; PAT Rs33.21 crore vs Rs33.01 crore.

• Reported profit reconciliation included Rs2.80 crore of prior-year adjustments and a Rs3.29 crore amalgamation adjustment; proposed dividend appropriation totaled Rs12.81 crore.

• Recommended dividend was Rs6/share, including a special silver-jubilee dividend of Rs2.50/share; rate unchanged from the prior year before the special component.

Outlook and guidance

• Focus planned on pharmaceutical sales, especially domestic and international formulations; portfolio trimming and exits may weigh short term, with benefits expected across operations.

• Russia strategy shifts toward private channels through a newly incorporated wholly owned subsidiary and a Moscow field force; promotion will concentrate on selected international markets.

• Indrad facility modernization, estimated at Rs30 crore, was targeted for completion during FY98 to meet current USFDA requirements.

• Planned R&D infrastructure investment of Rs35 crore over the next year; several new products were also planned for launch in FY98.